Parenteral arginine impairs intestinal adaptation following massive small bowel resection in a rat model.
The nitric oxide precursor L-arginine (ARG) has been shown to influence intestinal structure and absorptive function. It is also well known that the route of administration modulates the effects of ARG. The present study evaluated the effects of parenteral ARG on structural intestinal adaptation, cell proliferation, and apoptosis in a rat model of short bowel syndrome (SBS). Male Sprague-Dawley rats were divided into three experimental groups: Sham rats underwent bowel transection and reanastomosis, SBS rats underwent a 75% small bowel resection, and SBS-ARG rats underwent a 75% small bowel resection and were treated with ARG given subcutaneously at a dose of 300 mug/kg, once daily, from days 3 to 14. Parameters of intestinal adaptation, enterocyte proliferation, and enterocyte apoptosis were determined on day 15 following operation. The SBS rats demonstrated a significant increase in jejunal and ileal bowel and mucosal weight, villus height and crypt depth, and cell proliferation index compared with the sham group. The SBS-ARG animals demonstrated lower ileal bowel and mucosal weights, jejunal mucosal DNA and ileal mucosal protein, and jejunal and ileal villus height and crypt depth compared with SBS animals. The SBS-ARG rats also had a lower cell proliferation index in both jejunum and ileum and a greater enterocyte apoptotic index in ileum compared with the SBS-untreated group. In conclusion, in a rat model of SBS, parenteral arginine inhibits structural intestinal adaptation. Decreased cell proliferation and increased apoptosis are the main mechanisms responsible for decreased cell mass.
Sukhotnik
Igor
I
Department of Pediatric Surgery, Rappaport Faculty of Medicine, Bnai Zion Medical Center, Technion-Israel Institute of Technology, 47 Golomb St, P.O. Box 4940, Haifa 31048, Israel. igor-dr@internet-zahav.net
Mogilner
Jorge G
JG
Lerner
Aaron
A
Coran
Arnold G
AG
Lurie
Michael
M
Miselevich
Iness
I
Shiloni
Eitan
E
D000222:Adaptation, Physiological / Q000187:drug effects*; D000818:Animals; D017209:Apoptosis; D001120:Arginine / Q000008:administration & dosage / Q000494:pharmacology*; D049109:Cell Proliferation; D004195:Disease Models, Animal; D020895:Enterocytes / Q000502:physiology; D007082:Ileum / Q000503:physiopathology; D007279:Injections, Subcutaneous; D007422:Intestines / Q000503:physiopathology*; D007583:Jejunum / Q000503:physiopathology; D008297:Male; D009929:Organ Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D012778:Short Bowel Syndrome / Q000503:physiopathology*
D001120:Arginine